140 related articles for article (PubMed ID: 35731928)
1. Treatment Represents a Key Driver of Metastatic Cancer Evolution.
Christensen DS; Ahrenfeldt J; Sokač M; Kisistók J; Thomsen MK; Maretty L; McGranahan N; Birkbak NJ
Cancer Res; 2022 Aug; 82(16):2918-2927. PubMed ID: 35731928
[TBL] [Abstract][Full Text] [Related]
2. Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination.
Lawrence-Paul MR; Pan TC; Pant DK; Shih NNC; Chen Y; Belka GK; Feldman M; DeMichele A; Chodosh LA
Genome Med; 2024 Feb; 16(1):26. PubMed ID: 38321573
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.
Zhang W; Han W; Yu B; Zhao X; Lu G; Wu W; Zhang Y
Thorac Cancer; 2022 Jun; 13(11):1642-1650. PubMed ID: 35466584
[TBL] [Abstract][Full Text] [Related]
4. Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.
Kim H; Chae KJ; Yoon SH; Kim M; Keam B; Kim TM; Kim DW; Goo JM; Park CM
Eur Radiol; 2018 Feb; 28(2):861-868. PubMed ID: 28786010
[TBL] [Abstract][Full Text] [Related]
5. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
[TBL] [Abstract][Full Text] [Related]
6. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
7. Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC.
Xie T; Liu Z; Li Y; Wang S; Zhai Y; Teng F; Hao X; Wang Y; Wang H; Zhang X; Wu X; Ying J; Li J; Zhang Y; Deng Y; Xing P
Mol Cancer Res; 2023 Apr; 21(4):374-385. PubMed ID: 36534728
[TBL] [Abstract][Full Text] [Related]
8. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
[TBL] [Abstract][Full Text] [Related]
9. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
10. The application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients.
Powrózek T; Krawczyk P; Jarosz B; Mlak R; Wojas-Krawczyk K; Sawicki M; Stencel D; Trojanowski T; Milanowski J
Pathol Oncol Res; 2014 Oct; 20(4):945-51. PubMed ID: 24789720
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
Zeng Y; Guo T; Zhou Y; Zhao Y; Chu L; Chu X; Yang X; Ni J; Zhu Z
BMC Cancer; 2022 Feb; 22(1):198. PubMed ID: 35189835
[TBL] [Abstract][Full Text] [Related]
12. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
13. Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.
Tseng LH; De Marchi F; Pallavajjalla A; Rodriguez E; Xian R; Belchis D; Gocke CD; Eshleman JR; Illei P; Lin MT
Am J Clin Pathol; 2019 Oct; 152(5):570-581. PubMed ID: 31264684
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
Sullivan I; Planchard D
Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
[TBL] [Abstract][Full Text] [Related]
16. Genomic characterization of metastatic breast cancers.
Bertucci F; Ng CKY; Patsouris A; Droin N; Piscuoglio S; Carbuccia N; Soria JC; Dien AT; Adnani Y; Kamal M; Garnier S; Meurice G; Jimenez M; Dogan S; Verret B; Chaffanet M; Bachelot T; Campone M; Lefeuvre C; Bonnefoi H; Dalenc F; Jacquet A; De Filippo MR; Babbar N; Birnbaum D; Filleron T; Le Tourneau C; André F
Nature; 2019 May; 569(7757):560-564. PubMed ID: 31118521
[TBL] [Abstract][Full Text] [Related]
17. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Kujtan L; Subramanian J
Expert Rev Anticancer Ther; 2019 Jul; 19(7):547-559. PubMed ID: 30913927
[No Abstract] [Full Text] [Related]
19. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
